Conversation with The Cancer LetterFree Peter Tunney: How the largest art movement in history can help reduce cancer disparities April 27, 2018Vol.44 No.17By Paul Goldberg
Conversation with The Cancer LetterFree Manocherian: We have been unapologetic in advocating for 10% annual increases to NIH April 06, 2018Vol.44 No.14By Matthew Bin Han Ong
Conversation with The Cancer Letter University of Michigan gets $150 million to recruit cancer researchers, fund research March 30, 2018Vol.44 No.13By Paul Goldberg
Conversation with The Cancer Letter Goldwater’s Coleman: Right to Try patients don’t need permission from feds to save their own lives March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Conversation with The Cancer Letter NYU’s Caplan: Right to Try laws are meaningless, empty hot air, unethical, and utterly ineffective March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Porter: I can’t tell you how the Trump administration gets its budget numbers March 16, 2018Vol.44 No.11By Paul Goldberg
Conversation with The Cancer Letter Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable March 16, 2018Vol.44 No.11By Matthew Bin Han Ong
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
Conversation with The Cancer LetterFree PH.AI CEO Hyde: With Big Data, pharma will focus on the measurement of value March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Roche CEO O’Day: Our investment in Flatiron will accelerate their mission March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
